

III Workshop: Educational Program in Ovarian Cancer and BRCA

Porta Fira Hotel, Barcelona, 16th September 2016

Directors: Ana Oaknin & Judith Balmaña

10:00-10:10h: Welcome and Introduction

I session: Challenges in the underlying genetics of ovarian cancer

Chairs: José Palacios Calvo, Hospital Ramón y Cajal, Madrid, Spain

Alex Teulé, Institut Català Oncologia (ICO) Hospitalet, Barcelona, Spain

10:10-10:20: Pre-session knowledge testing

Chairs

10:20-10:40h: Genetic abnormalities and HRD in Ovarian Cancer: is there a reliable signature to guide therapy?

Maria José Garcia, Human Genetics Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain

10:40-11:10h Tumor testing in Ovarian Cancer: somatic or germline? Perspectives from the lab and from the clinics

Ana Vivancos, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Ignacio Romero, Instituto Valenciano de Oncología (IVO), Valencia, Spain

11:10-11:30h: Beyond BRCA1/BRCA2 Testing: The role of other genes in ovarian cancer susceptibility and treatment

Judith Balmaña, Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

11:30-12:00: Post-session knowledge testing and discussion

Chairs

12:00-12:20h Coffee break

II session: Tailoring the role of PARP inhibitors in Ovarian Cancer

Chairs: Andrés Poveda, Instituto Valenciano de Oncología (IVO), Valencia, Spain

Andrés Redondo, Hospital La Paz, Madrid, Spain

12:20-12:30: Pre-session knowledge testing

Chairs

12:30-12:50h PARP Inhibitors in the clinics: what we know and what we expect

Antonio González-Martín, MD Anderson Cancer Center, Madrid, Spain

12:50-13:10h: Mechanisms of Resistance to PARP Inhibitors. Preclinical and Clinical Data

Violeta Serra, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

Accreditation for CME requested



Supported requested:



13:10-13:30: Post-session knowledge testing and discussion
Chairs

13:30-14:30h Lunch

14:30-14:50h: How can we enhance the activity of PARP inhibitors?
Victor Rodriguez-Freixinós, Vall d'Hebron University Hospital. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

14:50-15:10h Molecular Rationale for developing Immunotherapy in Ovarian Cancer
Josep M^e Piulats, Institut Català Oncologia (ICO) Hospitalet, Barcelona, Spain

15:10-15:30: Post-session knowledge testing and discussion
Chairs

III session: The role of genetic counselors in the Ovarian Cancer Clinic

15:30- 16:00: What is the role of genetic counselors in Ovarian cancer in the era of genetics?
Irene Esteban, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

16:00-16:15: Discussion

16:15-16:30: Adjourn

Accreditation for CME requested



Supported requested:

